{"id":60222,"date":"2024-10-04T12:00:31","date_gmt":"2024-10-04T12:00:31","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/04\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/"},"modified":"2024-10-04T12:00:31","modified_gmt":"2024-10-04T12:00:31","slug":"onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/","title":{"rendered":"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr)"},"content":{"rendered":"<div>\n<p>LOUISVILLE, Ky., Oct.  04, 2024  (GLOBE NEWSWIRE) &#8212; Onco360<sup>\u00ae<\/sup>, the nation\u2019s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Beigene for Tevimbra<sup>\u00ae<\/sup>\u00a0(tislelizumab), approved for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. This indication was approved based on the Phase III RATIONALE-302, (NCT03430843) clinical trial, which compared Tislelizumab to\u00a0systemic chemotherapy.<sup>1<\/sup><\/p>\n<p>Tevimbra<sup>\u00ae<\/sup> (tislelizumab) is a PD-1 inhibitor that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing the PD-1 pathway mediated inhibition of the immune response, including the anti-tumor immune response. Esophageal cancer (EC) is the sixth most common cause of cancer-related deaths. ESCC is the most common histologic subtype of EC, accounting for nearly 90% of ECs.\u00a0Esophageal cancer is a rapidly fatal disease. Over two-thirds of patients have advanced or metastatic disease at the time of diagnosis, with an expected five-year survival rate of less than 6% for those with distant metastases.<sup>2<\/sup><\/p>\n<p>\u201cOnco360 is grateful for the opportunity to expand our partnership with the team at BeiGene and become the exclusive national specialty pharmacy provider for Tevimbra<sup>\u00ae<\/sup>,\u201d said Benito Fernandez. \u201cThe FDA approval of Tevimbra represents a new treatment option for patients suffering from unresectable or metastatic esophageal cancer, and as a chosen provider, we remain committed to providing patients, their caregivers, and providers with the highest level of quality and service.\u201d<\/p>\n<p>The FDA approval of Tevimbra<sup>\u00ae<\/sup> is based on the results of the Phase III RATIONALE-2 clinical trial, which evaluated 512 adult patients with unresectable advanced or metastatic esophageal (ESCC), randomized 1:1 to receive Tevimbra<sup>\u00ae<\/sup> 200mg IV every 3 weeks or investigator\u2019s choice IV systemic chemotherapy (paclitaxel, docetaxel, or irinotecan). All patients had received at least one prior anti-cancer systemic therapy. RATIONALE-302 demonstrated a statistically significant improvement in overall survival (OS) for patients randomized to Tevimbra<sup>\u00ae<\/sup> as compared with systemic chemotherapy.<\/p>\n<p>The most common (\u2265 20%) adverse reactions, including laboratory abnormalities, were increased glucose (46%), decreased hemoglobin (45%), decreased lymphocytes (43%), decreased sodium (34%), decreased albumin (33%), increased alkaline phosphatase (32%), anemia (31%), fatigue (28%), increased AST (27%), musculoskeletal pain (24%), decreased weight (23%), increased ALT (23%), and cough (22%).<\/p>\n<p>Please see the full Prescribing Information for Tevimbra<sup>\u00ae<\/sup><\/p>\n<p><strong>About Onco360 Oncology Pharmacy:<\/strong><br \/>Onco360 is the nation\u2019s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Specialty Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u4TCLKSN0e9LaoddgGFG9ltLxjIW7_6J6wiZs3ZIrhgyL6U5-oN0dOw8DjUXzD8NsyR7qlo9cjiT44hVlOal9g==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Onco360.com\">Onco360.com<\/a>.<\/p>\n<p><strong>Media Contact:<\/strong> Benito Fernandez, Chief Commercial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JPCON1CeU0ai75F443cy3TWlwHa7nJlrVZmXnV4hrK0dIZfXLlqv5ZaF1LxC3K1GcVvVh9UsAXZjbyPNwfausMQXzPTozElQ-31G34qLkcI9bAJyrkrF43pSUNvA-Zu1\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Benito.Fernandez@Onco360.com\">Benito.Fernandez@Onco360.com<\/a><br \/>516-640-1332<\/p>\n<p>References:<\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"margin-top:5pt;\">Lin Shen et al., RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable\/metastatic esophageal squamous cell carcinoma. <em>JCO<\/em>\u00a0<strong>39<\/strong>,\u00a04012-4012(2021). <\/li>\n<li style=\"margin-top:5pt;\">National Cancer Institute. Cancer stat facts: esophageal cancer. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N_nfQ9rzDMpFQLGMebqOabkhWQavaywM3JoN8-iidA8B43uU09qq817aICa3kAdGAVGXbQPkKPr2vfkmA4Enr11UhfYLERyz7GVg0bKzSY2M-diL7jOUshRhgy8NZMZBDrYImK7WNQzjspbeX11tRgvDwQD_7K1UpRHOstjrqOI=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/seer.cancer.gov\/statfacts\/html\/esoph.html<\/a>.<\/li>\n<\/ol>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDBiMTM4MTktZmNmNi00YjY3LWI0OWEtYjM1MjI3NmIxYmNlLTUwMDEyMjkzNw==\/tiny\/Onco360-Oncology-Pharmacy.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOUISVILLE, Ky., Oct. 04, 2024 (GLOBE NEWSWIRE) &#8212; Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Beigene for Tevimbra\u00ae\u00a0(tislelizumab), approved for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. This indication [&#8230;]\n","protected":false},"author":1,"featured_media":60223,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr) - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr)\" \/>\n<meta property=\"og:description\" content=\"LOUISVILLE, Ky., Oct. 04, 2024 (GLOBE NEWSWIRE) &#8212; Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected as a pharm\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-04T12:00:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Onco360-Oncology-Pharmacy.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr)\",\"datePublished\":\"2024-10-04T12:00:31+00:00\",\"dateModified\":\"2024-10-04T12:00:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/\"},\"wordCount\":530,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/\",\"name\":\"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr) - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-04T12:00:31+00:00\",\"dateModified\":\"2024-10-04T12:00:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr) - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/","og_locale":"en_US","og_type":"article","og_title":"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr)","og_description":"LOUISVILLE, Ky., Oct. 04, 2024 (GLOBE NEWSWIRE) &#8212; Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected as a pharm","og_url":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-04T12:00:31+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Onco360-Oncology-Pharmacy.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr)","datePublished":"2024-10-04T12:00:31+00:00","dateModified":"2024-10-04T12:00:31+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/"},"wordCount":530,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/","url":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/","name":"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr) - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-04T12:00:31+00:00","dateModified":"2024-10-04T12:00:31+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/onco360-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra-tislelizumab-jsgr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Onco360\u00ae Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra\u00ae (tislelizumab-jsgr)"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60222"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60222\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/60223"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}